vs

Side-by-side financial comparison of AMERISAFE INC (AMSF) and GRAIL, Inc. (GRAL). Click either name above to swap in a different company.

AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $43.6M, roughly 1.8× GRAIL, Inc.). AMERISAFE INC runs the higher net margin — 10.2% vs -227.5%, a 237.7% gap on every dollar of revenue. On growth, GRAIL, Inc. posted the faster year-over-year revenue change (14.0% vs 10.3%). Over the past eight quarters, GRAIL, Inc.'s revenue compounded faster (27.7% CAGR vs 2.8%).

AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.

GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.

AMSF vs GRAL — Head-to-Head

Bigger by revenue
AMSF
AMSF
1.8× larger
AMSF
$80.1M
$43.6M
GRAL
Growing faster (revenue YoY)
GRAL
GRAL
+3.7% gap
GRAL
14.0%
10.3%
AMSF
Higher net margin
AMSF
AMSF
237.7% more per $
AMSF
10.2%
-227.5%
GRAL
Faster 2-yr revenue CAGR
GRAL
GRAL
Annualised
GRAL
27.7%
2.8%
AMSF

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMSF
AMSF
GRAL
GRAL
Revenue
$80.1M
$43.6M
Net Profit
$8.1M
$-99.2M
Gross Margin
Operating Margin
-285.4%
Net Margin
10.2%
-227.5%
Revenue YoY
10.3%
14.0%
Net Profit YoY
-9.0%
-2.2%
EPS (diluted)
$0.43
$-2.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMSF
AMSF
GRAL
GRAL
Q1 26
$80.1M
Q4 25
$81.6M
$43.6M
Q3 25
$82.0M
$36.2M
Q2 25
$81.1M
$35.5M
Q1 25
$72.6M
$31.8M
Q4 24
$74.0M
$38.3M
Q3 24
$78.7M
$28.7M
Q2 24
$75.8M
$32.0M
Net Profit
AMSF
AMSF
GRAL
GRAL
Q1 26
$8.1M
Q4 25
$10.4M
$-99.2M
Q3 25
$13.8M
$-89.0M
Q2 25
$14.0M
$-114.0M
Q1 25
$8.9M
$-106.2M
Q4 24
$13.2M
$-97.1M
Q3 24
$14.3M
$-125.7M
Q2 24
$11.0M
$-1.6B
Operating Margin
AMSF
AMSF
GRAL
GRAL
Q1 26
Q4 25
15.6%
-285.4%
Q3 25
21.3%
-346.2%
Q2 25
21.5%
-446.9%
Q1 25
15.5%
-482.5%
Q4 24
22.7%
-358.0%
Q3 24
22.6%
-640.5%
Q2 24
18.1%
-5133.8%
Net Margin
AMSF
AMSF
GRAL
GRAL
Q1 26
10.2%
Q4 25
12.8%
-227.5%
Q3 25
16.9%
-245.8%
Q2 25
17.2%
-320.7%
Q1 25
12.3%
-333.6%
Q4 24
17.8%
-253.8%
Q3 24
18.2%
-438.7%
Q2 24
14.5%
-4958.8%
EPS (diluted)
AMSF
AMSF
GRAL
GRAL
Q1 26
$0.43
Q4 25
$0.55
$-2.37
Q3 25
$0.72
$-2.46
Q2 25
$0.73
$-3.18
Q1 25
$0.47
$-3.10
Q4 24
$0.69
$-1.49
Q3 24
$0.75
$-3.94
Q2 24
$0.57
$-51.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMSF
AMSF
GRAL
GRAL
Cash + ST InvestmentsLiquidity on hand
$34.2M
$249.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$246.6M
$2.6B
Total Assets
$2.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMSF
AMSF
GRAL
GRAL
Q1 26
$34.2M
Q4 25
$61.9M
$249.7M
Q3 25
$54.7M
$126.9M
Q2 25
$48.5M
$127.4M
Q1 25
$44.8M
$133.9M
Q4 24
$44.1M
$214.2M
Q3 24
$63.7M
$853.6M
Q2 24
$30.6M
$958.8M
Stockholders' Equity
AMSF
AMSF
GRAL
GRAL
Q1 26
$246.6M
Q4 25
$251.6M
$2.6B
Q3 25
$274.8M
$2.2B
Q2 25
$265.6M
$2.3B
Q1 25
$260.8M
$2.4B
Q4 24
$257.3M
$2.5B
Q3 24
$314.4M
$2.6B
Q2 24
$301.0M
$2.7B
Total Assets
AMSF
AMSF
GRAL
GRAL
Q1 26
Q4 25
$1.1B
$2.9B
Q3 25
$1.2B
$2.6B
Q2 25
$1.2B
$2.7B
Q1 25
$1.2B
$2.8B
Q4 24
$1.2B
$3.0B
Q3 24
$1.3B
$3.1B
Q2 24
$1.2B
$3.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMSF
AMSF
GRAL
GRAL
Operating Cash FlowLast quarter
$-63.8M
Free Cash FlowOCF − Capex
$-63.9M
FCF MarginFCF / Revenue
-146.5%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-299.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMSF
AMSF
GRAL
GRAL
Q1 26
Q4 25
$11.1M
$-63.8M
Q3 25
$10.7M
$-63.2M
Q2 25
$-8.4M
$-77.0M
Q1 25
$-1.8M
$-95.0M
Q4 24
$24.2M
Q3 24
$8.4M
$-104.6M
Q2 24
$-2.6M
$-171.8M
Free Cash Flow
AMSF
AMSF
GRAL
GRAL
Q1 26
Q4 25
$8.9M
$-63.9M
Q3 25
$9.8M
$-63.6M
Q2 25
$-9.5M
$-77.3M
Q1 25
$-1.8M
$-95.1M
Q4 24
$23.4M
Q3 24
$8.4M
$-105.6M
Q2 24
$-2.6M
$-173.2M
FCF Margin
AMSF
AMSF
GRAL
GRAL
Q1 26
Q4 25
10.9%
-146.5%
Q3 25
11.9%
-175.8%
Q2 25
-11.7%
-217.6%
Q1 25
-2.5%
-298.6%
Q4 24
31.5%
Q3 24
10.7%
-368.4%
Q2 24
-3.5%
-541.7%
Capex Intensity
AMSF
AMSF
GRAL
GRAL
Q1 26
Q4 25
2.6%
0.2%
Q3 25
1.1%
1.1%
Q2 25
1.3%
1.0%
Q1 25
0.0%
0.2%
Q4 24
1.1%
Q3 24
0.0%
3.4%
Q2 24
0.1%
4.3%
Cash Conversion
AMSF
AMSF
GRAL
GRAL
Q1 26
Q4 25
1.06×
Q3 25
0.77×
Q2 25
-0.61×
Q1 25
-0.20×
Q4 24
1.83×
Q3 24
0.59×
Q2 24
-0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMSF
AMSF

Segment breakdown not available.

GRAL
GRAL

Screening Revenue$42.3M97%
Developmental Services Revenue$1.3M3%

Related Comparisons